Abstract
During the last 50 years the global pandemic of obesity and associated life-threatening co-morbidities strongly promoted the development of anti-obesity pharmacotherapy. Sibutramine is an anti-obesity drug that in conjunction with lifestyle modifications reduces food intake and body weight. This may result from several effects: inhibition of presynaptic reuptake of monoaminergic neurotransmitters in the central nervous system, thereby suppressing appetite, induction of an increase in anorexigenic and a decrease in orexigenic neuropeptide secretion, induction of an increase in energy expenditure, and induction of peripheral sympathomimetic effects. The effects of sibutramine on anabolic and catabolic signals that regulate energy homeostasis in the hypothalamus are not completely understood. So, the aim of this review is to summarize the central mechanisms of action of sibutramine, responsible for its weight and food intake reducing potential. Despite being a useful drug in obesity treatment, awareness about the loss of long-term effectiveness and detrimental side effects of sibutramine has recently emerged. As a consequence, new drugs that produce safer and more persistent weight loss are currently undergoing clinical trials.
Keywords: Appetite, obesity, sibutramine, hypothalamus, weight loss, amplifying anorexigenic, type 2 diabetes
Current Neuropharmacology
Title: Sibutramine Effects on Central Mechanisms Regulating Energy Homeostasis
Volume: 10 Issue: 1
Author(s): Joao R. Araujo and Fatima Martel
Affiliation:
Keywords: Appetite, obesity, sibutramine, hypothalamus, weight loss, amplifying anorexigenic, type 2 diabetes
Abstract: During the last 50 years the global pandemic of obesity and associated life-threatening co-morbidities strongly promoted the development of anti-obesity pharmacotherapy. Sibutramine is an anti-obesity drug that in conjunction with lifestyle modifications reduces food intake and body weight. This may result from several effects: inhibition of presynaptic reuptake of monoaminergic neurotransmitters in the central nervous system, thereby suppressing appetite, induction of an increase in anorexigenic and a decrease in orexigenic neuropeptide secretion, induction of an increase in energy expenditure, and induction of peripheral sympathomimetic effects. The effects of sibutramine on anabolic and catabolic signals that regulate energy homeostasis in the hypothalamus are not completely understood. So, the aim of this review is to summarize the central mechanisms of action of sibutramine, responsible for its weight and food intake reducing potential. Despite being a useful drug in obesity treatment, awareness about the loss of long-term effectiveness and detrimental side effects of sibutramine has recently emerged. As a consequence, new drugs that produce safer and more persistent weight loss are currently undergoing clinical trials.
Export Options
About this article
Cite this article as:
R. Araujo Joao and Martel Fatima, Sibutramine Effects on Central Mechanisms Regulating Energy Homeostasis, Current Neuropharmacology 2012; 10 (1) . https://dx.doi.org/10.2174/157015912799362788
DOI https://dx.doi.org/10.2174/157015912799362788 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Therapies Targeting Innate Immunity for Fighting Inflammation in Atherosclerosis
Current Pharmaceutical Design Surgical Ventricular Restoration: An Operation To Reverse Remodeling - The Basic Science (Part I)
Current Cardiology Reviews Recent Advances in the Synthesis of Biologically Active Cinnoline, Phthalazine and Quinoxaline Derivatives
Current Organic Chemistry Gene-Wide Approach: New Frontiers in Cardiovascular Genetic Epidemiology
Current Hypertension Reviews Pre-Clinical and Clinical Evaluation of Nuclear Tracers for the Molecular Imaging of Vulnerable Atherosclerosis: An Overview
Current Medicinal Chemistry Anesthetic Cardioprotection in Relation to Mitochondria: Basic Science
Current Pharmaceutical Design Effects of Olive Oil on TNF-α and IL-6 in Humans: Implication in Obesity and Frailty
Endocrine, Metabolic & Immune Disorders - Drug Targets Intracranial Collateral Flow Estimated by Color Velocity Imaging Quantification Ultrasound: A Protector of Recurrent Stroke in Patient with Carotid Stenosis?
Current Neurovascular Research Taste and Hypertension in Humans: Targeting Cardiovascular Disease
Current Pharmaceutical Design Importance of Receptor-targeted Systems in the Battle Against Atherosclerosis
Current Pharmaceutical Design Radiolabelled Quinoline Derivaties for the PET Imaging of Peripheral Benzodiazepine Receptor
Current Medical Imaging Hypertriglyceridemia - Common Causes, Prevention and treatment Strategies
Current Cardiology Reviews Are Calcium Channel Blockers First-Line Drugs for the Treatment of Hypertension and Cardiovascular Disease?
Current Hypertension Reviews Withdrawal Notice: Electrophoresis as a Tool for Early Cancer Diagnosis
Anti-Cancer Agents in Medicinal Chemistry Heart Failure
Current Hypertension Reviews The IL23/Th17 Pathway as a Therapeutic Target in Chronic Inflammatory Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Current Concepts on Cardiovascular Stent Devices
Mini-Reviews in Medicinal Chemistry Editorial: Time for Earlier and More Intensive Preventive Therapy
Current Vascular Pharmacology Breast Cancer Chemoprevention: Current Perspectives
Current Enzyme Inhibition Diet Bioactive Compounds: Implications for Oxidative Stress and Inflammation in the Vascular System
Endocrine, Metabolic & Immune Disorders - Drug Targets